Sarepta Therapeutics (NASDAQ:SRPT) Price Target Lowered to $75.00 at HC Wainwright

Sarepta Therapeutics (NASDAQ:SRPT) had its price objective decreased by HC Wainwright from $80.00 to $75.00 in a research note released on Tuesday morning,Benzinga reports. HC Wainwright currently has a sell rating on the biotechnology company’s stock. HC Wainwright also issued estimates for Sarepta Therapeutics’ Q1 2025 earnings at $2.35 EPS, Q2 2025 earnings at $2.64 EPS, Q3 2025 earnings at $2.73 EPS, Q4 2025 earnings at $2.84 EPS and FY2025 earnings at $10.54 EPS.

Other equities research analysts have also issued reports about the company. Piper Sandler reduced their target price on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 27th. Cantor Fitzgerald upgraded shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $152.00 to $167.00 in a report on Thursday, November 7th. Citigroup dropped their target price on shares of Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th. Guggenheim boosted their price target on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Finally, StockNews.com lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, twenty have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $175.55.

Sarepta Therapeutics Stock Performance

Sarepta Therapeutics stock opened at $126.01 on Tuesday. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The firm has a market cap of $12.04 billion, a P/E ratio of 100.81 and a beta of 0.77. Sarepta Therapeutics has a 1-year low of $83.97 and a 1-year high of $173.25. The firm has a 50-day moving average of $122.56 and a 200-day moving average of $131.44.

Institutional Trading of Sarepta Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of SRPT. Innealta Capital LLC purchased a new stake in shares of Sarepta Therapeutics during the second quarter valued at approximately $31,000. Sunbelt Securities Inc. lifted its position in Sarepta Therapeutics by 446.2% in the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 232 shares in the last quarter. Huntington National Bank boosted its stake in Sarepta Therapeutics by 150.9% during the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 175 shares during the last quarter. Nkcfo LLC bought a new stake in shares of Sarepta Therapeutics in the 2nd quarter worth $43,000. Finally, Riggs Asset Managment Co. Inc. raised its stake in shares of Sarepta Therapeutics by 33.3% in the second quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 75 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.